Generics

Overview

In Spain, Bentley manufactures and markets approximately 129 products of various dosages and strengths which include approximately 180 product presentations, or SKUs, in four primary therapeutic areas: cardiovascular, gastrointestinal, central nervous system and infectious diseases. Bentley markets these products primarily in Spain and have developed alliances with other companies that market our products, pursuant to license and supply agreements, in other countries, including Portugal, Greece, the United Kingdom, Germany, Austria, Morocco, Poland and the Czech Republic. In addition, we manufacture products that are marketed by other companies both in Spain and elsewhere. Bentley’s generic and branded generic products are marketed to physicians, pharmacists and hospitals by its three Spanish sales and marketing organizations: Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar. We also market over-the-counter products through Laboratorios Rimafar. There are approximately 179,000 physicians and 21,000 pharmacies in Spain.

Bentley continually adds to its product portfolio in response to increasing market demand for generic and branded generic therapeutic agents and, when appropriate, divest portfolio products considered to be redundant or that have become non-strategic. The Company manufactures its finished dosage pharmaceutical products in its Spanish manufacturing facility which received approval from the U.S. Food and Drug Administration, or FDA, for the manufacture of its first U.S. generic product which was launched in the fourth quarter of 2006.

In August 2005, Bentley formed an Irish subsidiary, Bentley Pharmaceuticals Ireland Limited, to assist in generic product sales and marketing throughout the EU. The facility received its first marketing approval by the Irish Medicines Board in 2005 and launched its first product in the fourth quarter of 2006.

The information posted is as of 06/29/07 and, to our knowledge, was timely and accurate when posted. We are under no obligation to update or remove outdated information other than as required by applicable law or regulation.